^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
GASTROClear Test

Company:
MiRXES
Type:
CE Marked
Evidence

News

8ms
Mirxes receives FDA’s Breakthrough Device Designation for GASTROClearTM to advance blood-based cancer early detection (Mirxes Press Release)
"Mirxes Corporation USA, the wholly owned subsidiary of Mirxes Pte Ltd...announced today that its flagship product GASTROClearTM, a PCR-based in vitro diagnostic test for early detection of gastric (stomach) cancer, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA)."
FDA event
|
GASTROClear Test
8ms
MiRxes gets $50M in Series D funding, applies to Hong Kong Limited stock exchange (Genomeweb)
"MiRxes said Wednesday that it has completed a Series D funding round totaling $50 million, which will help accelerate the Singapore-based firm's development of cancer early detection blood tests and other preventive healthcare solutions."
Financing
|
GASTROClear Test
over1year
DIAGNOSTIC PERFORMANCE OF GASTROCLEAR FOR DETECTING GASTRIC CANCER IN THE JAPANESE POPULATION (UEGW 2022)
 GASTROClear yielded a competent diagnostic ability for GC in the Japanese population and has a potential to contribute to efficient stratification for the risk of GCs.
Clinical
|
CA 19-9 (Cancer antigen 19-9)
|
GASTROClear Test